Literature DB >> 24076559

Adverse effects of systemic glucose absorption with peritoneal dialysis: how good is the evidence?

Rajnish Mehrotra1, Ian H de Boer, Jonathan Himmelfarb.   

Abstract

PURPOSE OF REVIEW: Treatment of end-stage renal disease with peritoneal dialysis is associated with an obligatory absorption of carbohydrates with both glucose and icodextrin-based dialysate. In this review, we examine the evidence linking this obligatory absorption with adverse systemic effects. RECENT
FINDINGS: Systemic glucose absorption is associated with worse glycemic control; this can be ameliorated with glucose-sparing peritoneal dialysis regimens. The studies examining the benefit of glucose-sparing regimens on dyslipidemia are inconsistent and the magnitude of benefit is potentially small. There are no studies demonstrating any improvement in clinically meaningful patient outcomes with glucose-sparing regimens.
SUMMARY: Although it is conceivable that the obligatory carbohydrate absorption with peritoneal dialysis increases systemic cardiovascular risk, this premise has not been systematically or rigorously examined to date, there are no robust biomarkers to measure the risk, modification of which may favorably improve outcomes, and whether glucose-sparing peritoneal dialysis regimens will lower the putative risk is currently unknown. Hence, there is a compelling need to bridge our gap in understanding the role of systemic glucose absorption with peritoneal dialysis on the health of individuals undergoing peritoneal dialysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24076559     DOI: 10.1097/MNH.0b013e328365b3d1

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  7 in total

1.  Should glucose-sparing prescriptions be expected to reduce the cardiovascular risk of peritoneal dialysis patients?

Authors:  Rajnish Mehrotra; Ian H de Boer
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

2.  Is peritoneal dialysis causing a measurable burden of inflammatory and endothelial injury on top of metabolic syndrome?

Authors:  M Miler; N Nikolac; D Segulja; S Kackov Maslac; I Celap; K Altabas; S Sefer; A M Simundic
Journal:  J Endocrinol Invest       Date:  2016-09-06       Impact factor: 4.256

3.  Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy.

Authors:  Maria Bartosova; Betti Schaefer; Justo Lorenzo Bermejo; Silvia Tarantino; Felix Lasitschka; Stephan Macher-Goeppinger; Peter Sinn; Bradley A Warady; Ariane Zaloszyc; Katja Parapatics; Peter Májek; Keiryn L Bennett; Jun Oh; Christoph Aufricht; Franz Schaefer; Klaus Kratochwill; Claus Peter Schmitt
Journal:  J Am Soc Nephrol       Date:  2017-10-18       Impact factor: 10.121

4.  Equivalent Fall Risk in Elderly Patients on Hemodialysis and Peritoneal Dialysis.

Authors:  Janine Farragher; Tasleem Rajan; Ernest Chiu; Ozkan Ulutas; George Tomlinson; Wendy L Cook; Sarbjit V Jassal
Journal:  Perit Dial Int       Date:  2015-12-03       Impact factor: 1.756

5.  Excessive Weight Gain during the First Year of Peritoneal Dialysis Is Associated with Inflammation, Diabetes Mellitus, and a Rapid Decrease in Residual Renal Function.

Authors:  Jwa-Kyung Kim; Young-Su Kim; Young Rim Song; Hyung Jik Kim; Sung Gyun Kim; Sung Jin Moon
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

Review 6.  Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.

Authors:  Dongsheng Cheng; Yang Fei; Yumei Liu; Junhui Li; Yuqiang Chen; Xiaoxia Wang; Niansong Wang
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

7.  Skin Autofluorescence and Mortality in Patients on Peritoneal Dialysis.

Authors:  Emília Mácsai; Attila Benke; István Kiss
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.